AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

Recruitingn/aAges 18 Years - anyAllChina-Japan Friendship Hospital
💬

In plain words

What the trial is, and whether it could suit you

Definitive radiotherapy is one of the important methods for inoperable locally advanced lung cancer. The recommended dose for definitive radiotherapy is 60-70Gy, and the optimal dose is still uncertain. Residual lesion after radiotherapy is a risk factor for recurrence. High doses to targeted tumor areas can effectively improve the local control rate, while minimizing toxic side effects. The regression pattern of primary lesions in lung caner after radiotherapy has not been clarified. This study intends to retrospectively collect clinical data of lung cancer patients with definitive radiotherapy, and explore the pattern of tumor regression after radiotherapy. It will help optimize the radiotherapy plan for lung cancer, so as to improve the efficacy and prognosis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥18 years old; 2. Stage II-III lung cancer with a clear pathological diagnosis report or medical record, not undergoing surgery before radiotherapy; 3. The primary lung lesion received definitive radiotherapy (defined as conventional fractionation radiotherapy with dose ≥50Gy, stereotactic radiotherapy with biologically effective dose ≥100Gy); 4. The target lesion of the lung receiving radiotherapy can be measured; 5. Imaging data can be obtained before and after radiotherapy; 6. Complete radiotherapy as planned, or the actual received dose has reached the defined definitive dose. Exclusion Criteria: 1. Before radiotherapy, the primary lesion of the lung had received local treatment such as surgery or ablative treatment; 2. The radiotherapy plan was not completed, and the actual dose received did not reach the definitive dose (defined as conventional fractionation radiotherapy with dose \<50Gy, stereotactic radiotherapy with biologically effective dose \<100Gy); 3. Required imaging data cannot be obtained; 4. Other conditions considered by the investigator to be inappropriate for enrollment.
💊

What it tests

  • Not listed
📍

Where

2 sites
China-Japan Friendship Hospital
Beijing, China
Renmin Hospital of Wuhan University
Wuhan, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy